Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in Acute Ischemic Stroke
NCT01955707Phase 2Completed
- Sponsor
- Biogen
- Start
- Jan 2014
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of natalizumab in ischemic stroke, sponsored by Biogen. Started Jan 2014; status: completed.
02
Drugs
natalizumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT01955707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01955707.